Sarah Leong

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier et al. · Blood · 2022 · 86 citations

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS

Jad Othman, Ho Pui Jeff Lam, Sarah Leong et al. · Blood Neoplasia · 2024 · 26 citations · Full text

CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy

Sarah Leong, Sarah Inglott, Foteini Papaleonidopoulou et al. · Blood Advances · 2020 · 23 citations · Full text

Autoimmune Disease, Allergy, T-regulatory Cell +9

S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL

Caroline Hasselbalch Riley, Martin Hutchings, Seungho Yoon et al. · HemaSphere · 2022 · 18 citations · Full text

Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, Mittal Shah et al. · Blood · 2023 · 14 citations